Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026)

Corvus Pharmaceuticals' Return on Capital Employed history spans 11 years, with the latest figure at 31.94% for Q1 2026.

  • Quarterly Return on Capital Employed rose 2493.0% to 31.94% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 31.94% through Mar 2026, up 2493.0% year-over-year, with the annual reading at 70.87% for FY2025, 5533.0% up from the prior year.
  • Return on Capital Employed came in at 31.94% for Q1 2026, up from 64.7% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 31.94% in Q1 2026 to a low of 164.21% in Q3 2024.
  • The 5-year median for Return on Capital Employed is 55.89% (2023), against an average of 60.86%.
  • Year-over-year, Return on Capital Employed tumbled -11510bps in 2024 and then soared 11367bps in 2025.
  • Corvus Pharmaceuticals' Return on Capital Employed stood at 51.25% in 2022, then dropped by -9bps to 55.89% in 2023, then tumbled by -73bps to 96.8% in 2024, then surged by 33bps to 64.7% in 2025, then surged by 51bps to 31.94% in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Return on Capital Employed are 31.94% (Q1 2026), 64.7% (Q4 2025), and 50.54% (Q3 2025).